Veeva Systems (NYSE:VEEV) Board Authorizes Share Repurchase Program

Veeva Systems (NYSE:VEEV) declared that its Board of Directors has approved a stock buyback program on Monday, January 5th, RTT News reports. The company plans to buyback $2.00 billion in shares. This buyback authorization allows the technology company to reacquire up to 5.5% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Veeva Systems Stock Performance

NYSE VEEV traded up $1.81 on Monday, hitting $221.30. 1,574,923 shares of the stock were exchanged, compared to its average volume of 1,426,041. Veeva Systems has a 52-week low of $201.54 and a 52-week high of $310.50. The firm has a market capitalization of $36.38 billion, a P/E ratio of 43.05, a P/E/G ratio of 1.62 and a beta of 1.07. The stock has a fifty day moving average price of $250.89 and a two-hundred day moving average price of $272.11.

Veeva Systems (NYSE:VEEV) last released its quarterly earnings data on Thursday, November 20th. The technology company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.95 by $0.09. Veeva Systems had a net margin of 27.93% and a return on equity of 13.68%. The firm had revenue of $0.81 million for the quarter, compared to the consensus estimate of $792.37 million. During the same period last year, the firm earned $1.75 earnings per share. The company’s quarterly revenue was up 16.0% on a year-over-year basis. Veeva Systems has set its FY 2026 guidance at 7.930-7.93 EPS and its Q4 2026 guidance at 1.920-1.920 EPS. Sell-side analysts expect that Veeva Systems will post 4.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on VEEV shares. Canaccord Genuity Group reissued a “buy” rating on shares of Veeva Systems in a research note on Tuesday, November 25th. BMO Capital Markets began coverage on shares of Veeva Systems in a research note on Thursday, November 13th. They issued a “market perform” rating and a $300.00 target price on the stock. Robert W. Baird increased their target price on Veeva Systems from $314.00 to $319.00 and gave the company an “outperform” rating in a research note on Friday, November 21st. Wells Fargo & Company dropped their target price on Veeva Systems from $341.00 to $333.00 and set an “overweight” rating for the company in a report on Tuesday, November 25th. Finally, Barclays reduced their target price on Veeva Systems from $325.00 to $305.00 and set an “overweight” rating on the stock in a research note on Friday, November 21st. Eighteen investment analysts have rated the stock with a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $307.42.

Insider Buying and Selling

In other Veeva Systems news, insider Eleni Nitsa Zuppas sold 6,000 shares of the stock in a transaction dated Tuesday, October 7th. The stock was sold at an average price of $306.62, for a total value of $1,839,720.00. Following the sale, the insider owned 25,325 shares of the company’s stock, valued at $7,765,151.50. This trade represents a 19.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 10.30% of the stock is owned by company insiders.

Veeva Systems Company Profile

Veeva Systems (NYSE: VEEV) is a cloud software company that develops industry-specific applications and data solutions for the global life sciences sector. Founded in 2007 and headquartered in Pleasanton, California, Veeva focuses on helping pharmaceutical, biotechnology, medical device and consumer health companies manage regulated content, clinical and regulatory processes, quality systems, and commercial operations in a compliant, cloud-native environment. The company completed its initial public offering in 2013 and has since expanded its product suite and international footprint.

Veeva’s product portfolio centers on its Vault platform and related application suites, which provide content and data management, clinical trial and regulatory workflows, quality management, and structured commercial capabilities such as customer relationship management and promotional content management.